ACADIA Pharmaceuticals Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending March 30, 2021 was $738 Thousand (a -33.39% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) decreased by -60.02%
  • Annual Goodwill and Intangible Assets (Total) for 2020 was $1.11 Million (a -57.14% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2019 was $2.59 Million (a -36.36% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2018 was $4.06 Million (a -26.65% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of ACADIA Pharmaceuticals Inc.

Most recent Goodwill and Intangible Assets (Total)of ACAD including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.74
2020 $1.11 $1.48 $1.85 $2.22 $1.11
2019 $2.59 $2.95 $3.32 $3.69 $2.59
2018 $4.06 $4.43 $4.8 $5.17 $4.06
2017 $5.54 $5.91 $6.28 $6.65 $5.54
2016 $7.02 $7.39 $7.75 $7.02

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.